Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call [Yahoo! Finance]
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock? [Yahoo! Finance]
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Canaccord Genuity Group Inc. from $78.00 to $130.00. They now have a "buy" rating on the stock.